Belite Bio (BLTE) announced that the FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. There are currently no approved treatments for STGD1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength
- Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio
- Belite Bio Advances Clinical Trials Amid Financial Challenges
- Belite Bio Advances Tinlarebant Trials with Positive Interim Results
- Belite Bio reports Q1 EPS (27c), consensus (37c)